International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
β Scribed by Stefan Zeuzem; Jean-Michel Pawlotsky; Esther Lukasiewicz; Michael von Wagner; Ioannis Goulis; Yoav Lurie; Elia Gianfranco; Jan-Maarten Vrolijk; Juan I. Esteban; Christophe Hezode; Martin Lagging; Francesco Negro; Alexandre Soulier; Elke Verheij-Hart; Bettina Hansen; Ronen Tal; Carlo Ferrari; Solko W. Schalm; Avidan U. Neumann; for the DITTO-HCV Study Group
- Book ID
- 116650789
- Publisher
- Elsevier Science
- Year
- 2005
- Tongue
- English
- Weight
- 165 KB
- Volume
- 43
- Category
- Article
- ISSN
- 0168-8278
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract One hundred fiftyβfive chronic hepatitis C patients were assigned at random to receive natural lymphoblastoid interferon (IFN)Ξ±βn1, s.c., for 13 months in one of three treatment regimens: initial daily induction with 10 million units (MU) followed (group 1, nβ=β50) or not (group 2, nβ=β
The aim of this study was to determine whether 12 months course of interferon alfa (IFN-a) therapy could improve the beneficial effect of IFN in chronic hepatitis C. Eighty-eight patients were treated with natural IFNa for either 28 weeks (45 cases) or 52 weeks (43 cases). Sustained response was ach